Alfentanil for Minimal Sedation: Data Sheet, Data Collection Tips, Study Flow, FAQs
 

Overview: A study designed to determine the efficacy and safety of alfentanil for procedures requiring minimal sedation

Study Endpoints: 1. Respiratory depression as assessed by ETCO2 2. Mental status as assessed by OAAS and patient report.

Eligible Patients: Adult (≥18 y.o.) patients undergoing a minimal procedural sedation for any reason. This means they would normally be given fentanyl, versed, or combination of fentanyl and versed

Study Design: Prospective, observational trial.
 

Anticipated Benefits: ETCO2 monitoring mandated by the study may improve safety of procedure.
 

Potential Risks: The usual risks associated with minimal sedation.
 

Research Associate’s Role: The RA is responsible for identifying, enrolling, and collecting data from eligible patients for this study.  The RA is in charge of setting up and putting away the End-Tidal CO₂ monitor used to obtain data during the procedure.  After the study, the RA conducts interviews of the physician and the patient. This study can be combined with the "Capnography Study"
 

Physician’s Role: The RA will ask you to notify them of any conscious sedations being performed so that they may enter the patient into the study.  You will be asked to perform the sedation using either alfentanil. Once the procedure is over, you will be asked to complete a short questionnaire about the success of the procedure.
 

Location of Study Packets: Team Center B